Physician profile
Windy G Mitchell
NPI 1487613667
$10,796.01
in general payments reported to CMS, 2019-2025
67 companies · $2,514 in 2025
The $2,514 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,906 · 2022: $2,300 · 2023: $2,607 · 2024: $1,469 · 2025: $2,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,327 · Education: $665 · Long Term Medical Supply Or Device Loan: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,327.18 |
| Education | $664.63 |
| Long Term Medical Supply Or Device Loan | $598.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,109.38 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $750.97 | 2021-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $573.78 | 2021-2025 | Calquence, Tagrisso, Lynparza |
| Amgen INC. | $556.19 | 2021-2023 | Lumakras, Kyprolis, Blincyto |
| Genentech USA, INC. | $542.41 | 2021-2025 | Tecentriq, Alecensa, Venclexta |
| Daiichi Sankyo INC. | $512.79 | 2021-2025 | Enhertu, Injectafer, Vanflyta |
| Janssen Biotech, INC. | $495.72 | 2022-2025 | Rybrevant, Imbruvica, Darzalex |
| Merck Sharp & Dohme LLC | $458.93 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $450.77 | 2021-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Regeneron Healthcare Solutions, INC. | $309.08 | 2021-2025 | Libtayo |
| Seagen INC. | $293.20 | 2021-2025 | Adcetris, Tukysa, Padcev |
| Genzyme Corporation | $280.25 | 2021-2025 | |
| Celgene Corporation | $261.57 | 2021-2024 | Reblozyl, Pomalyst, Opdualag |
| Sanofi-Aventis U.S. LLC | $259.69 | 2021-2023 | |
| Incyte Corporation | $248.78 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Windy Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.